We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$65.9M
Cap. Flow %
12.88%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 64.14%
2 Miscellaneous 24.59%
3 Technology 4.38%
4 Communication Services 1.99%
5 Industrials 1.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
76
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.7M 0.33%
+15,000
New +$1.75M
AAP icon
77
Advance Auto Parts
AAP
$2.53B
$1.67M 0.33%
11,237
-4,822
-30% -$775K
PRQR icon
78
ProQR Therapeutics
PRQR
$267M
$1.65M 0.32%
330,000
+130,000
+65% +$572K
AXSM icon
79
Axsome Therapeutics
AXSM
$11.2B
$1.56M 0.31%
+401,000
New +$1.92M
EVOK
80
DELISTED
Evoke Pharma
EVOK
$1.55M 0.3%
+3,472
New +$1.42M
TSEM icon
81
Tower Semiconductor
TSEM
$24.8B
$1.55M 0.3%
67,155
-16,785
-20% -$368K
MGNX icon
82
MacroGenics
MGNX
$263M
$1.51M 0.3%
81,200
– –
FPRX
83
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.45M 0.28%
40,000
– –
OEF icon
84
CALL
iShares S&P 100 ETF
OEF
$20.3B
$1.39M 0.27%
100
-99,900
-100% -$10.3M
PDSB icon
85
PDS Biotechnology
PDSB
$61M
$1.37M 0.27%
7,500
– –
XENE icon
86
Xenon Pharmaceuticals
XENE
$5.55B
$1.31M 0.26%
328,029
– –
MA icon
87
Mastercard
MA
$496B
$1.3M 0.25%
11,525
+700
+6% +$76.7K
RARX
88
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.28M 0.25%
60,000
– –
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.2M 0.23%
242,000
-100,000
-29% -$962K
ZGNX
90
DELISTED
Zogenix, Inc.
ZGNX
$1.08M 0.21%
+100,000
New +$1.01M
VTGN icon
91
VistaGen Therapeutics
VTGN
$10.4M
$1.07M 0.21%
18,137
– –
TMO icon
92
Thermo Fisher Scientific
TMO
$243B
$1.06M 0.21%
6,913
+550
+9% +$84.1K
PTN
93
Palatin Technologies
PTN
$18.6M
$952K 0.19%
2,325
– –
RPRX
94
DELISTED
Repros Therapeutics Inc.
RPRX
$935K 0.18%
778,800
-200,000
-20% -$250K
RCKT icon
95
Rocket Pharmaceuticals
RCKT
$384M
$804K 0.16%
100,441
– –
GNMX
96
DELISTED
Aevi Genomic Medicine Inc
GNMX
$753K 0.15%
405,000
-45,000
-10% -$204K
SEDG icon
97
SolarEdge
SEDG
$2.21B
$729K 0.14%
46,750
+20,547
+78% +$286K
ANAB icon
98
AnaptysBio
ANAB
$1.63B
$708K 0.14%
+25,500
New +$594K
ATXS
99
DELISTED
Astria Therapeutics
ATXS
$621K 0.12%
6,467
+1
+0% +$138
VIRX
100
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$513K 0.1%
3,571
– –
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $65.9M of net new capital in Q1 2017, opening 35 new positions and adding to 30 existing holdings. Its largest new stake was Biogen: 75,000 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $11.9M trimmed.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.